Literature DB >> 24709236

Effect of intracameral use of dexamethasone on corneal endothelial cells.

Ahmad Zeeshan Jamil1, Arslan Ahmed2, Khurram Azam Mirza2.   

Abstract

OBJECTIVE: To evaluate the effect of intracameral dexamethasone on corneal endothelium. STUDY
DESIGN: Quasi experimental study. PLACE AND DURATION OF STUDY: Layton Rehmatulla Benevolent Trust Eye Hospital, Lahore, from May 2011 to January 2012.
METHODOLOGY: Study subjects were adults of either gender with senile cataract who underwent phacoemulsification. They were divided in two groups, each had 110 patients. Group-A received subconjunctival injection of dexamethasone (2 mg/0.5 ml) at the end of surgery while group-B received intracameral injection of dexamethasone (0.4 mg/0.1 ml) at the end of surgery. Endothelial cell count was performed by specular microscopy pre-operatively and postoperatively at first week, first month and three months. Outcome measures included changes in endothelial cell count. Results were compared using t-test for means.
RESULTS: There were 55 (50%) males and 55 (50%) females in group-A and 44 (40%) males and 66 (60%) females in group-B. In group-A, there were 66 (60%) right and 44 (40%) left eyes while group-B had 62 (56.36%) right and 48 (43.63%) left eyes. Mean age in group-A was 55.17 ± 5.93 years and 54.87 ± 5.55 years in group-B. Mean phacoemulsification time in group-A was 1.92 ± 0.63 minutes and 1.82 ± 0.54 minutes in group-B. After 3 months, in group-A, there was 7.55 ± 1.19% endothelial cell loss while in group-B, there was 7.63 ± 1.10% endothelial cell loss. The difference between the two groups was not statistically significant (p=0.614).
CONCLUSION: Use of intracameral dexamethasone at the end of cataract surgery is safe for corneal endothelium.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24709236     DOI: 04.2014/JCPSP.245248

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  6 in total

1.  The corneal effects of intravitreal dexamethasone implantation.

Authors:  Alper Halil Bayat; Gamze Karataş; Muhammet Mustafa Kurt; Mustafa Nuri Elçioğlu
Journal:  Ther Adv Ophthalmol       Date:  2020-08-06

2.  Comparison of safety and number of post-operative visits of patients in convenient day versus conventional first day follow-up after phacoemulsification.

Authors:  Zahid Kamal; Ahmad Zeeshan Jamil; Hira Shuja Khokhar; Farah Huma
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

Review 3.  Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.

Authors:  Tirth J Shah; Mandi D Conway; Gholam A Peyman
Journal:  Clin Ophthalmol       Date:  2018-11-01

4.  Anterior chamber migration of a sustained-release dexamethasone intravitreal implant: A case report and review of literature.

Authors:  Parthopratim Dutta Majumder; Amit H Palkar; Nikita Pathare; Jyotirmay Biswas
Journal:  Oman J Ophthalmol       Date:  2019 May-Aug

5.  Comparative Outcomes of Standard Perioperative Eye Drops, Intravitreal Triamcinolone Acetonide-Moxifloxacin, and Intracameral Dexamethasone-Moxifloxacin-Ketorolac in Cataract Surgery.

Authors:  Robin K Kuriakose; Soungmin Cho; Saman Nassiri; Frank S Hwang
Journal:  J Ophthalmol       Date:  2022-07-19       Impact factor: 1.974

6.  Intracameral Triamcinolone Acetonide Versus Topical Dexamethasone: A Comparison of Anti-inflammatory Effects After Phacoemulsification.

Authors:  Kamran Haider Shaheen; Muhammad Saad Ullah; Syed Ahmer Hussain; Aamir Furqan
Journal:  Cureus       Date:  2020-04-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.